Gynecologic Oncology

QLS5132 led to a 50% ORR and manageable safety in PROC, supporting CLDN6 as a promising ADC target in early-phase clinical development.

Early evidence suggests a dual bispecific strategy may be able to move the needle forward for patients with platinum-resistant ovarian cancer or endometrial cancer.

Maurie Markman, MD, highlights the frequently complex arena of goals of care discussions in oncology.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

A significant increase in treatment completion was observed among Black women with high-risk endometrial cancer who received 1:1 peer support.

Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.

Abemaciclib plus letrozole was safe and active in advanced/recurrent endometrioid endometrial carcinoma.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

Read below to hear from Drs Markman and Slomovitz on the sessions and abstracts they’re looking forward to at this year’s SGO Annual Meeting on Women’s Cancer.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

The regulatory agency green lit the use of MyChoice CDx as a companion diagnostic for niraparib in advanced ovarian cancer

Maurie Markman, MD, discusses ethical dilemmas in oncology trials, balancing patient welfare with research integrity and regulatory goals.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

Robert Neff, MD, discusses how the increasing uptake of HPV vaccination could affect the treatment of patients with cervical cancer.

Robert Neff, MD, discusses how molecular HPV genotyping and testing can be integrated into cervical cancer screening algorithms.

The FDA has approved pembrolizumab plus paclitaxel with/without bevacizumab for PD-L1–positive platinum-resistant ovarian cancer.

Robert Neff, MD, highlights the role of oncology-led advocacy in improving screening uptake in cervical cancer.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in January 2026.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Dana M. Chase, MD, Robert Neff, MD, and Maurie Markman, MD, comment on the current state of HPV vaccination and screening during cervical cancer awareness month.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

Robert Neff, MD, discusses the potential benefits of self-collected HPV testing and the challenges of implementing this screening method in practice.